Akums Drugs Performance Analyzed

Akums Drugs, a company that makes medicines for other companies, saw its stock price jump recently. The stock price went up 8% to reach ₹480 per share. This happened because many people bought and sold the stock quickly. At the same time, the overall stock market (BSE Sensex) was going down a little.

Key Points

• Stock jumped 8% to ₹480, driven by high trading volume.
• Bulk deals involved significant stake changes by major investors.
• Akums reported a 35.8% drop in profit year-over-year.
• Revenue decreased slightly by 1.5% compared to the previous year.
• API prices falling and flat volumes pressured the CDMO business.
• Management focused on long-term value and strategic business growth.

Investors bought a lot of Akums shares. One big buyer was Ruby QC Investment Holdings, who sold their entire stake (about 4.62% of the company) to other buyers. This sale was at a price of ₹428 per share. ICICI Prudential Mutual Fund also bought a similar amount of shares.

Akums itself makes medicines for other companies. In the last quarter (Q2 FY26), the company’s profits were down 35.8% compared to the year before. They made less money selling medicines.

The company’s total value is approximately ₹7,161.43 crore. Their stock price has gone up and down over the last year, reaching a high of ₹678.8 and a low of ₹407.4.

The company’s leaders, like Sandeep Jain, are working on a plan. They want to stay the best at making medicines for other companies. They’re also trying to grow their sales in India and other countries and reduce losses.

“Our goal is to continue growing and providing value to our shareholders, even during challenging times.”